enGene

About:

enGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins.

Website: https://www.engene.com/

Top Investors: Blue Owl, Hercules Capital, OrbiMed, Fonds de solidarité FTQ, Marshall Wace

Description:

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.